APA (7th ed.) Citation

Agarwal, N., Azad, A. A., Carles, J., Fay, A. P., Matsubara, N., Heinrich, D., . . . Fizazi, K. (2023). Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): A randomised, placebo-controlled, phase 3 trial. The lancet, 402(10398), . https://doi.org/10.1016/S0140-6736(23)01055-3

Chicago Style (17th ed.) Citation

Agarwal, Neeraj, et al. "Talazoparib Plus Enzalutamide in Men with First-line Metastatic Castration-resistant Prostate Cancer (TALAPRO-2): A Randomised, Placebo-controlled, Phase 3 Trial." The Lancet 402, no. 10398 (2023). https://doi.org/10.1016/S0140-6736(23)01055-3.

MLA (9th ed.) Citation

Agarwal, Neeraj, et al. "Talazoparib Plus Enzalutamide in Men with First-line Metastatic Castration-resistant Prostate Cancer (TALAPRO-2): A Randomised, Placebo-controlled, Phase 3 Trial." The Lancet, vol. 402, no. 10398, 2023, https://doi.org/10.1016/S0140-6736(23)01055-3.